| SCHEDULE OF SEGMENT REPORTING |
Segment
data for the year ended December 31, 2024 is as follows:
SCHEDULE OF SEGMENT REPORTING
| | |
Octomera | | |
Therapies | | |
Eliminations | | |
Consolidated | |
| | |
(in
thousands) | |
| Revenues | |
$ | 533 | | |
$ | 525 | | |
$ | (23 | ) | |
$ | 1,035 | |
| Cost of revenues* | |
| (1,351 | ) | |
| (633 | ) | |
| 710 | | |
| (1,274 | ) |
| Gross profit (loss) | |
| (818 | ) | |
| (108 | ) | |
| 687 | | |
| (239 | ) |
| Cost of development services and research
and development expenses* | |
| (4,530 | ) | |
| (5,169 | ) | |
| 697 | | |
| (9,002 | ) |
| Operating expenses* | |
| (3,557 | ) | |
| (10,716 | ) | |
| 4,178 | | |
| (10,095 | ) |
| Impairment of investment** | |
| (6,509 | ) | |
| (11,829 | ) | |
| - | | |
| (18,338 | ) |
| Share in net income of associated companies | |
| - | | |
| (8 | ) | |
| - | | |
| (8 | ) |
| Profit from deconsolidation | |
| - | | |
| - | | |
| 4,480 | | |
| 4,480 | |
| Other income, net | |
| 1,022 | | |
| (416 | ) | |
| - | | |
| 606 | |
| Depreciation and amortization | |
| (1,558 | ) | |
| (771 | ) | |
| 243 | | |
| (2,086 | ) |
| Loss from extinguishment in connection with
convertible loan | |
| - | | |
| (5,422 | ) | |
| - | | |
| (5,422 | ) |
| Credit loss on convertible loan receivable | |
| - | | |
| - | | |
| - | | |
| - | |
| Financial Expenses, net | |
| (4,682 | ) | |
| 49 | | |
| 125 | | |
| (4,508 | ) |
| Finance fees related
to convertible loans to equity | |
| - | | |
| (4,304 | ) | |
| - | | |
| (4,304 | ) |
| * | | Excluding Depreciation,
amortization and impairment expenses |
| ** | | Relates to impairment
expenses on certain property, plant and equipment. |
Segment
data for the year ended December 31, 2023 is as follows:
| | |
Octomera | | |
Therapies | | |
Eliminations | | |
Consolidated | |
| | |
(in
thousands) | |
| Revenues | |
$ | 68 | | |
$ | 515 | | |
$ | (53 | ) | |
$ | 530 | |
| Cost of revenues* | |
| (9,505 | ) | |
| (690 | ) | |
| 4,421 | | |
| (5,774 | ) |
| Gross profit (loss) | |
| (9,437 | ) | |
| (175 | ) | |
| 4,368 | | |
| (5,244 | ) |
| Cost of development services and research
and development expenses* | |
| (9,211 | ) | |
| (5,811 | ) | |
| 4,711 | | |
| (10,311 | ) |
| Operating expenses* | |
| (37,878 | ) | |
| (7,102 | ) | |
| 9,892 | | |
| (35,088 | ) |
| Impairment of investment | |
| - | | |
| (699 | ) | |
| - | | |
| (699 | ) |
| Share in net income of associated companies | |
| - | | |
| (74 | ) | |
| (660 | ) | |
| (734 | ) |
| Profit from deconsolidation | |
| - | | |
| - | | |
| (5,343 | ) | |
| (5,343 | ) |
| Other income, net | |
| 1 | | |
| 3 | | |
| - | | |
| 4 | |
| Depreciation and amortization | |
| (1,765 | ) | |
| (782 | ) | |
| 987 | | |
| (1,560 | ) |
| Credit loss on convertible loan receivable | |
| - | | |
| (2,688 | ) | |
| - | | |
| (2,688 | ) |
| Loss from extinguishment in connection with
convertible loan | |
| - | | |
| (283 | ) | |
| - | | |
| (283 | ) |
| Financial Expenses,
net | |
| (573 | ) | |
| (2,004 | ) | |
| 78 | | |
| (2,499 | ) |
| * | | Excluding Depreciation,
amortization and impairment expenses |
|